Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILICOFCM: Lifestyle and Sacubitril/Valsartan in HCM
NCT05366101Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Apr 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacubitril + valsartan in hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Peak Oxygen Consumption at 4 months. Started Apr 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05366101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366101.